Table 2.
Baseline demographic and clinical characteristics
| MCI | AD dementia | Total | |
|---|---|---|---|
| N | 88 | 60 | 148 |
| Age, years (mean, SD) | 70.7 (7.2)** | 66.9 (8.2) | 69.2 (7.8) |
| Sex (male/female) | 46/42 | 31/29 | 77/71 |
| MMSE (median, IQR) | 27 (3)*** | 24 (5) | 26 (4) |
| MTA score (median, IQR) | |||
| Left hemisphere | 2 (2) | 1 (2) | 2 (2) |
| Right hemisphere | 2 (1) | 2 (2) | 2 (2) |
| Aβ + (nn, CSF Aβ42/ [11C] PiB-PET) | 88/0 | 57/3 | 145/3 |
| Phosphorylated tau (n, CSF p-tau +/-) | 46/4 | 33/8 | 79/12 |
| Total tau (n, CSF t-tau +/-) | 44/6 | 33/8 | 77/14 |
| Medication use (n/%) | |||
| Anticholinergics | 4 (5%) | 6 (10%) | 10 (7%) |
| Antidepressants | 9 (10%) | 5 (8%) | 14 (9%) |
| AEDs | 1 (1%) | 3 (5%) | 4 (3%) |
| Antipsychotics | 1 (1%) | 1 (2%) | 2 (1%) |
| Benzodiazepines | 3 (3%) | 5 (8%) | 8 (5%) |
SD Standard deviation, MMSE Mini mental state examination, IQR Inter-quartile range, MTA Medial temporal lobe atrophy, Aβ + Amyloid beta positive, as measured by cerebrospinal fluid Aβ42 concentration or [15] C-labeled Pittsburgh Compound-B positron emission topography examination, AEDs Anti-epileptic drugs
**p < .01, *** p < .001